Current and Future Targets of Antiviral Therapy in the Hepatitis C Virus Life Cycle

References

• Scheel TK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies . Nat. Med.19 ( 7 ), 837 – 849 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Thomas DL . Global control of hepatitis C: where challenge meets opportunity . Nat. Med.19 ( 7 ), 850 – 858 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bartenschlager R , PeninF , LohmannV , AndreP . Assembly of infectious hepatitis C virus particles . Trends. Microbiol.19 ( 2 ), 95 – 103 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Catanese MT , UryuK , KoppMet al. Ultrastructural analysis of hepatitis C virus particles . Proc. Natl Acad. Sci. USA110 ( 23 ), 9505 – 9510 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gastaminza P , DrydenKA , BoydBet al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture . J. Virol.84 ( 21 ), 10999 – 11009 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Merz A , LongG , HietMSet al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome . J. Biol. Chem.286 ( 4 ), 3018 – 3032 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Khan AG , WhidbyJ , MillerMTet al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2 . Nature509 ( 7500 ), 381 – 384 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kong L , GiangE , NieusmaTet al. Hepatitis C virus E2 envelope glycoprotein core structure . Science342 ( 6162 ), 1090 – 1094 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Agnello V , AbelG , ElfahalM , KnightGB , ZhangQX . Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor . Proc. Natl Acad. Sci. USA96 ( 22 ), 12766 – 12771 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Albecka A , BelouzardS , Op de BeeckAet al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle . Hepatology55 ( 4 ), 998 – 1007 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Barth H , SchaferC , AdahMIet al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate . J. Biol. Chem.278 ( 42 ), 41003 – 41012 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Germi R , CranceJM , GarinDet al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption . J. Med. Virol.68 ( 2 ), 206 – 215 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Monazahian M , BohmeI , BonkSet al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus . J. Med. Virol.57 ( 3 ), 223 – 229 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Pileri P , UematsuY , CampagnoliSet al. Binding of hepatitis C virus to CD81 . Science282 ( 5390 ), 938 – 941 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Scarselli E , AnsuiniH , CerinoRet al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus . EMBO J.21 ( 19 ), 5017 – 5025 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Evans MJ , von HahnT , TscherneDMet al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry . Nature446 ( 7137 ), 801 – 805 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ploss A , EvansMJ , GaysinskayaVAet al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells . Nature457 ( 7231 ), 882 – 886 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sainz B Jr . BarrettoN , MartinDNet al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor . Nat. Med.18 ( 2 ), 281 – 285 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Martin DN , UprichardSL . Identification of transferrin receptor 1 as a hepatitis C virus entry factor . Proc. Natl Acad. Sci. USA110 ( 26 ), 10777 – 10782 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dorner M , HorwitzJA , DonovanBMet al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice . Nature501 ( 7466 ), 237 – 241 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dorner M , HorwitzJA , RobbinsJBet al. A genetically humanized mouse model for hepatitis C virus infection . Nature474 ( 7350 ), 208 – 211 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bankwitz D , SteinmannE , BitzegeioJet al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes . J. Virol.84 ( 11 ), 5751 – 5763 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Dao Thi VL , GranierC , ZeiselMBet al. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps . J. Biol. Chem.287 ( 37 ), 31242 – 31257 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zahid MN , TurekM , XiaoFet al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination . Hepatology57 ( 2 ), 492 – 504 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Harris HJ , FarquharMJ , MeeCJet al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry . J. Virol.82 ( 10 ), 5007 – 5020 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Farquhar MJ , HarrisHJ , DiskarMet al. Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity . J. Virol.82 ( 17 ), 8797 – 8811 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Brazzoli M , BianchiA , FilippiniSet al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes . J. Virol.82 ( 17 ), 8316 – 8329 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lupberger J , ZeiselMB , XiaoFet al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy . Nat. Med.17 ( 5 ), 589 – 595 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zona L , LupbergerJ , Sidahmed-AdrarNet al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex . Cell Host Microbe13 ( 3 ), 302 – 313 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sourisseau M , MichtaML , ZonyCet al. Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies . PLoS Pathog.9 ( 3 ), e1003244 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• McCartney EM , EyreNS , BeardMR . Border patrol intensifies for hepatitis C virus entry . Hepatology54 ( 4 ), 1472 – 1475 ( 2011 ).
   PubMedGoogle Scholar
• Meuleman P , CataneseMT , VerhoyeLet al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo . Hepatology55 ( 2 ), 364 – 372 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vercauteren K , Van Den EedeN , MesalamAAet al. Successful anti-SR-BI mAb therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents . Hepatology doi: 10.1002/hep.27196 ( 2014 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Meuleman P , HesselgesserJ , PaulsonMet al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo . Hepatology48 ( 6 ), 1761 – 1768 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Xiao F , FofanaI , ThumannCet al. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C . Gut doi: 10.1136/gutjnl-2013-306155 ( 2014 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Syder AJ , LeeH , ZeiselMBet al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors . J. Hepatol.54 ( 1 ), 48 – 55 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zhu H , Wong-StaalF , LeeHet al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals . J. Infect. Dis.205 ( 4 ), 656 – 662 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Baldick CJ , WichroskiMJ , PendriAet al. A novel small molecule inhibitor of hepatitis C virus entry . PLoS Pathog.6 ( 9 ), e1001086 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Calland N , AlbeckaA , BelouzardSet al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry . Hepatology55 ( 3 ), 720 – 729 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ciesek S , von HahnT , ColpittsCCet al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry . Hepatology54 ( 6 ), 1947 – 1955 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Haid S , NovodomskaA , GentzschJet al. A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes . Gastroenterology143 ( 1 ), 213 – 222e215 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zeisel MB , FelmleeDJ , BaumertTF . Hepatitis C virus entry . Curr. Top. Microbiol. Immunol.369 , 87 – 112 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dibrov SM , DingK , BrunnNDet al. Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches . Proc. Natl Acad. Sci. USA109 ( 14 ), 5223 – 5228 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dibrov SM , ParsonsJ , CarnevaliMet al. Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site . J. Med. Chem.57 ( 5 ), 1694 – 1707 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jirasko V , MontserretR , LeeJYet al. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly . PLoS Pathog.6 ( 12 ), e1001233 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ma Y , AnantpadmaM , TimpeJMet al. Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins . J. Virol.85 ( 1 ), 86 – 97 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Popescu CI , CallensN , TrinelDet al. NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly . PLoS Pathog.7 ( 2 ), e1001278 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Stapleford KA , LindenbachBD . Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes . J. Virol.85 ( 4 ), 1706 – 1717 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Horner SM , GaleMJr . Regulation of hepatic innate immunity by hepatitis C virus . Nat. Med.19 ( 7 ), 879 – 888 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bacon BR , GordonSC , LawitzEet al. Boceprevir for previously treated chronic HCV genotype 1 infection . N. Engl. J. Med.364 ( 13 ), 1207 – 1217 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jacobson IM , McHutchisonJG , DusheikoGet al. Telaprevir for previously untreated chronic hepatitis C virus infection . N. Engl. J. Med.364 ( 25 ), 2405 – 2416 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Poordad F , McConeJJr . BaconBRet al. Boceprevir for untreated chronic HCV genotype 1 infection . N. Engl. J. Med.364 ( 13 ), 1195 – 1206 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zeuzem S , AndreoneP , PolSet al. Telaprevir for retreatment of HCV infection . N. Engl. J. Med.364 ( 25 ), 2417 – 2428 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Egger D , WolkB , GosertRet al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex . J. Virol.76 ( 12 ), 5974 – 5984 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Ferraris P , BlanchardE , RoingeardP . Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes . J. Gen. Virol.91 ( Pt 9 ), 2230 – 2237 ( 2010 ).
   PubMedGoogle Scholar
• Romero-Brey I , MerzA , ChiramelAet al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication . PLoS Pathog.8 ( 12 ), e1003056 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ferraris P , BeaumontE , UzbekovRet al. Sequential biogenesis of host cell membrane rearrangements induced by hepatitis C virus infection . Cell. Mol. Life Sci.70 ( 7 ), 1297 – 1306 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Paul D , HoppeS , SaherG , Krijnse-LockerJ , BartenschlagerR . Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment . J. Virol.87 ( 19 ), 10612 – 10627 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lohmann V , KornerF , KochJ , HerianU , TheilmannL , BartenschlagerR . Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line . Science285 ( 5424 ), 110 – 113 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Morikawa K , LangeCM , GouttenoireJet al. Nonstructural protein 3–4A: the Swiss army knife of hepatitis C virus . J. Viral Hepat.18 ( 5 ), 305 – 315 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jankowsky E , BowersH . Remodeling of ribonucleoprotein complexes with DExH/D RNA helicases . Nucleic Acids Res.34 ( 15 ), 4181 – 4188 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Gouttenoire J , RoingeardP , PeninF , MoradpourD . Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B . J. Virol.84 ( 24 ), 12529 – 12537 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Paul D , Romero-BreyI , GouttenoireJet al. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes . J. Virol.85 ( 14 ), 6963 – 6976 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Miller JF , ChongPY , ShotwellJBet al. Hepatitis C replication inhibitors that target the viral NS4B protein . J. Med. Chem.57 ( 5 ), 2107 – 2120 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Phillips B , CaiR , DelaneyWet al. Highly potent HCV NS4B inhibitors with activity against multiple genotypes . J. Med. Chem.57 ( 5 ), 2161 – 2166 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Esser-Nobis K , Romero-BreyI , GantenTMet al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B . Hepatology57 ( 3 ), 953 – 963 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Love RA , BrodskyO , HickeyMJ , WellsPA , CroninCN . Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus . J. Virol.83 ( 9 ), 4395 – 4403 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL , MarcotrigianoJ , GorbalenyaAE , RiceCM . The NS5A protein of hepatitis C virus is a zinc metalloprotein . J. Biol. Chem.279 ( 47 ), 48576 – 48587 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL , MarcotrigianoJ , RiceCM . Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase . Nature435 ( 7040 ), 374 – 379 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Appel N , PietschmannT , BartenschlagerR . Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain . J. Virol.79 ( 5 ), 3187 – 3194 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL , FossKL , TreadawayJC , RiceCM . Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein . J. Virol.82 ( 3 ), 1073 – 1083 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Appel N , ZayasM , MillerSet al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly . PLoS Pathog.4 ( 3 ), e1000035 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Masaki T , SuzukiR , MurakamiKet al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles . J. Virol.82 ( 16 ), 7964 – 7976 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Tellinghuisen TL , FossKL , TreadawayJ . Regulation of hepatitis C virion production via phosphorylation of the NS5A protein . PLoS Pathog.4 ( 3 ), e1000032 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lemay KL , TreadawayJ , AnguloI , TellinghuisenTL . A hepatitis C virus NS5A phosphorylation site that regulates RNA replication . J. Virol.87 ( 2 ), 1255 – 1260 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ross-Thriepland D , HarrisM . Insights into the complexity and functionality of hepatitis C virus NS5A phosphorylation . J. Virol.88 ( 3 ), 1421 – 1432 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Salloum S , TaiAW . Treating hepatitis C infection by targeting the host . Transl. Res.159 ( 6 ), 421 – 429 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gao M , NettlesRE , BelemaMet al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect . Nature465 ( 7294 ), 96 – 100 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Scheel TK , GottweinJM , MikkelsenLS , JensenTB , BukhJ . Recombinant HCV variants with NS5A from genotypes 1–7 have different sensitivities to an NS5A inhibitor but not interferon-alpha . Gastroenterology140 ( 3 ), 1032 – 1042 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Belda O , Targett-AdamsP . Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein . Virus Res.170 ( 1–2 ), 1 – 14 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM . NS5A inhibitors in the treatment of hepatitis C . J. Hepatol.59 ( 2 ), 375 – 382 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lee C , MaH , HangJQet al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein . Virology414 ( 1 ), 10 – 18 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Qiu D , LemmJA , O’BoyleDR2ndet al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization . J. Gen. Virol.92 ( Pt 11 ), 2502 – 2511 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Targett-Adams P , GrahamEJ , MiddletonJet al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action . J. Virol.85 ( 13 ), 6353 – 6368 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Fridell RA , QiuD , ValeraL , WangC , RoseRE , GaoM . Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 . J. Virol.85 ( 14 ), 7312 – 7320 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lemm JA , O’BoyleD2nd , LiuMet al. Identification of hepatitis C virus NS5A inhibitors . J. Virol.84 ( 1 ), 482 – 491 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ascher DB , WielensJ , NeroTL , DoughtyL , MortonCJ , ParkerMW . Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA . Sci. Rep.4 , 4765 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Guedj J , DahariH , RongLet al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life . Proc. Natl Acad. Sci. USA110 ( 10 ), 3991 – 3996 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• McGivern DR , MasakiT , WillifordSet al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors . Gastroenterology147 ( 2 ), 453 – 462 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Berger C , Romero-BreyI , RadujkovicDet al. Daclatasvir-like inhibitors of NS5A block early biogenesis of HCV-induced membranous replication factories, independent of RNA replication . Gastroenterology147 ( 2 ), 453 – 562 ( 2014 ).
   PubMedGoogle Scholar
• Jordheim LP , DurantelD , ZoulimF , DumontetC . Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases . Nat. Rev. Drug Discov.12 ( 6 ), 447 – 464 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM . The science of direct-acting antiviral and host-targeted agent therapy . Antivir. Ther.17 ( 6 Pt B ), 1109 – 1117 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sofia MJ . Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?Antiviral Res.107 , 119 – 124 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Arnold JJ , SharmaSD , FengJYet al. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides . PLoS Pathog.8 ( 11 ), e1003030 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Haudecoeur R , PeuchmaurM , Ahmed-BelkacemA , PawlotskyJM , BoumendjelA . Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research . Med. Res. Rev.33 ( 5 ), 934 – 984 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Fenaux M , EngS , LeavittSAet al. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase . Antimicrob. Agents Chemother.57 ( 2 ), 804 – 810 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lazerwith SE , LewW , ZhangJet al. Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection . J. Med. Chem.57 ( 5 ), 1893 – 1901 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lemm JA , LiuM , GentlesRGet al. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase . Antimicrob. Agents Chemother.58 ( 6 ), 3485 – 3495 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM . New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development . Semin. Liver Dis.34 ( 1 ), 22 – 29 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rupp D , BartenschlagerR . Targets for antiviral therapy of hepatitis C . Semin. Liver Dis.34 ( 1 ), 9 – 21 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Alvisi G , MadanV , BartenschlagerR . Hepatitis C virus and host cell lipids: an intimate connection . RNA Biol.8 ( 2 ), 258 – 269 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Berger KL , CooperJD , HeatonNSet al. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication . Proc. Natl Acad. Sci. USA106 ( 18 ), 7577 – 7582 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Borawski J , TrokeP , PuyangXet al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication . J. Virol.83 ( 19 ), 10058 – 10074 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Reiss S , RebhanI , BackesPet al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment . Cell Host Microbe9 ( 1 ), 32 – 45 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Tai AW , BenitaY , PengLFet al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication . Cell Host Microbe5 ( 3 ), 298 – 307 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Trotard M , Lepere-DouardC , RegeardMet al. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening . FASEB J.23 ( 11 ), 3780 – 3789 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Vaillancourt FH , PiloteL , CartierMet al. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication . Virology387 ( 1 ), 5 – 10 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Berger KL , KellySM , JordanTX , TartellMA , RandallG . Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication . J. Virol.85 ( 17 ), 8870 – 8883 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Reiss S , HarakC , Romero-BreyIet al. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A . PLoS Pathog.9 ( 5 ), e1003359 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bianco A , ReghellinV , DonniciLet al. Metabolism of phosphatidylinositol 4-kinase IIIalpha-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity . PLoS Pathog.8 ( 3 ), e1002576 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vaillancourt FH , BraultM , PiloteLet al. Evaluation of phosphatidylinositol-4-kinase IIIalpha as a hepatitis C virus drug target . J. Virol.86 ( 21 ), 11595 – 11607 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Harak C , RadujkovicD , TaveneauCet al. Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis c virus replication . J. Virol.88 ( 17 ), 9909 – 9926 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Amemiya F , MaekawaS , ItakuraYet al. Targeting lipid metabolism in the treatment of hepatitis C virus infection . J. Infect. Dis.197 ( 3 ), 361 – 370 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ikeda M , AbeK , YamadaM , DansakoH , NakaK , KatoN . Different anti-HCV profiles of statins and their potential for combination therapy with interferon . Hepatology44 ( 1 ), 117 – 125 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kapadia SB , ChisariFV . Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids . Proc. Natl Acad. Sci. USA102 ( 7 ), 2561 – 2566 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Wang C , GaleMJr , KellerBCet al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication . Mol. Cell18 ( 4 ), 425 – 434 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Ye J , WangC , SumpterRJr , BrownMS , GoldsteinJL , GaleMJr . Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation . Proc. Natl Acad. Sci. USA100 ( 26 ), 15865 – 15870 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Hirata Y , IkedaK , SudohMet al. Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis . PLoS Pathog.8 ( 8 ), e1002860 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Shi ST , LeeKJ , AizakiH , HwangSB , LaiMM . Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2 . J. Virol.77 ( 7 ), 4160 – 4168 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Weng L , HirataY , AraiMet al. Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner . J. Virol.84 ( 22 ), 11761 – 11770 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sakamoto H , OkamotoK , AokiMet al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy . Nat. Chem. Biol.1 ( 6 ), 333 – 337 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Boulant S , DouglasMW , MoodyL , BudkowskaA , Targett-AdamsP , McLauchlanJ . Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner . Traffic9 ( 8 ), 1268 – 1282 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• McLauchlan J , LembergMK , HopeG , MartoglioB . Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets . EMBO J.21 ( 15 ), 3980 – 3988 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Targett-Adams P , HopeG , BoulantS , McLauchlanJ . Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production . J. Biol. Chem.283 ( 24 ), 16850 – 16859 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Herker E , HarrisC , HernandezCet al. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1 . Nat. Med.16 ( 11 ), 1295 – 1298 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Miyanari Y , AtsuzawaK , UsudaNet al. The lipid droplet is an important organelle for hepatitis C virus production . Nat. Cell Biol.9 ( 9 ), 1089 – 1097 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Gawlik K , BaughJ , ChatterjiU , LimPJ , BobardtMD , GallayPA . HCV core residues critical for infectivity are also involved in core-NS5A complex formation . PLoS ONE9 ( 2 ), e88866 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Camus G , HerkerE , ModiAAet al. Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core . J. Biol. Chem.288 ( 14 ), 9915 – 9923 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Salloum S , WangH , FergusonC , PartonRG , TaiAW . Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets . PLoS Pathog.9 ( 8 ), e1003513 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vogt DA , CamusG , HerkerEet al. Lipid droplet-binding protein TIP47 regulates hepatitis C virus RNA replication through interaction with the viral NS5A protein . PLoS Pathog.9 ( 4 ), e1003302 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Boson B , GranioO , BartenschlagerR , CossetFL . A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly . PLoS Pathog.7 ( 7 ), e1002144 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Shavinskaya A , BoulantS , PeninF , McLauchlanJ , BartenschlagerR . The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly . J. Biol. Chem.282 ( 51 ), 37158 – 37169 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Gentzsch J , BrohmC , SteinmannEet al. hepatitis c Virus p7 is critical for capsid assembly and envelopment . PLoS Pathog.9 ( 5 ), e1003355 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lindenbach BD , RiceCM . The ins and outs of hepatitis C virus entry and assembly . Nat. Rev. Microbiol.11 ( 10 ), 688 – 700 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Counihan NA , RawlinsonSM , LindenbachBD . Trafficking of hepatitis C virus core protein during virus particle assembly . PLoS Pathog.7 ( 10 ), e1002302 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ariumi Y , KurokiM , MakiMet al. The ESCRT system is required for hepatitis C virus production . PLoS ONE6 ( 1 ), e14517 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Corless L , CrumpCM , GriffinSD , HarrisM . Vps4 and the ESCRT-III complex are required for the release of infectious hepatitis C virus particles . J. Gen. Virol.91 ( Pt 2 ), 362 – 372 ( 2010 ).
   PubMedGoogle Scholar
• Tamai K , ShiinaM , TanakaNet al. Regulation of hepatitis C virus secretion by the Hrs-dependent exosomal pathway . Virology422 ( 2 ), 377 – 385 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chang KS , JiangJ , CaiZ , LuoG . Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture . J. Virol.81 ( 24 ), 13783 – 13793 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Gastaminza P , ChengG , WielandS , ZhongJ , LiaoW , ChisariFV . Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion . J. Virol.82 ( 5 ), 2120 – 2129 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Huang H , SunF , OwenDMet al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins . Proc. Natl Acad. Sci. USA104 ( 14 ), 5848 – 5853 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Jiang J , LuoG . Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles . J. Virol.83 ( 24 ), 12680 – 12691 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Benga WJ , KriegerSE , DimitrovaMet al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles . Hepatology51 ( 1 ), 43 – 53 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Boyer A , DumansA , BeaumontE , EtienneL , RoingeardP , MeunierJC . The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles . J. Biol. Chem.289 ( 27 ), 18904 – 18913 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cun W , JiangJ , LuoG . The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus . J. Virol.84 ( 21 ), 11532 – 11541 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Frentzen A , Anggakusuma , GurlevikEet al. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells . Hepatology59 ( 1 ), 78 – 88 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hueging K , DoepkeM , VieyresGet al. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly . J. Virol.88 ( 3 ), 1433 – 1446 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Long G , HietMS , WindischMP , LeeJY , LohmannV , BartenschlagerR . Mouse hepatic cells support assembly of infectious hepatitis C virus particles . Gastroenterology141 ( 3 ), 1057 – 1066 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Vogt A , ScullMA , FrilingTet al. Recapitulation of the hepatitis C virus life cycle in engineered murine cell lines . Virology444 ( 1–2 ), 1 – 11 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• McCaffrey K , BooI , TewierekK , EdmundsML , PoumbouriosP , DrummerHE . Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function . J. Virol.86 ( 7 ), 3961 – 3974 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vieyres G , ThomasX , DescampsV , DuverlieG , PatelAH , DubuissonJ . Characterization of the envelope glycoproteins associated with infectious hepatitis C virus . J. Virol.84 ( 19 ), 10159 – 10168 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wozniak AL , GriffinS , RowlandsDet al. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production . PLoS Pathog.6 ( 9 ), e1001087 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Griffin S , StgelaisC , OwsiankaAM , PatelAH , RowlandsD , HarrisM . Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel . Hepatology48 ( 6 ), 1779 – 1790 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Steinmann E , PeninF , KallisS , PatelAH , BartenschlagerR , PietschmannT . Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions . PLoS Pathog.3 ( 7 ), e103 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Luscombe CA , HuangZ , MurrayMG , MillerM , WilkinsonJ , EwartGD . A novel hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues . Antiviral Res.86 ( 2 ), 144 – 153 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• DeVita RJ , PintoS . Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors . J. Med. Chem.56 ( 24 ), 9820 – 9825 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Li Q , ZhangYY , ChiuSet al. Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle . PLoS Pathog.10 ( 5 ), e1004163 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Li Y , KowdleyKV . MicroRNAs in common human diseases . Genomics Proteomics Bioinformatics10 ( 5 ), 246 – 253 ( 2012 ).
   PubMedGoogle Scholar
• van Rooij E , KauppinenS . Development of microRNA therapeutics is coming of age . EMBO Mol. Med.6 ( 7 ), 851 – 864 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jopling CL , YiM , LancasterAM , LemonSM , SarnowP . Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA . Science309 ( 5740 ), 1577 – 1581 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Machlin ES , SarnowP , SaganSM . Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex . Proc. Natl Acad. Sci. USA108 ( 8 ), 3193 – 3198 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jangra RK , YiM , LemonSM . Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122 . J. Virol.84 ( 13 ), 6615 – 6625 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Li Y , MasakiT , YamaneD , McGivernDR , LemonSM . Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication . Proc. Natl Acad. Sci. USA110 ( 5 ), 1881 – 1886 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Chang J , NicolasE , MarksDet al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1 . RNA Biol.1 ( 2 ), 106 – 113 ( 2004 ).
   PubMedGoogle Scholar
• Jopling C . Liver-specific microRNA-122: biogenesis and function . RNA Biol.9 ( 2 ), 137 – 142 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Baek J , KangS , MinH . MicroRNA-targeting therapeutics for hepatitis C . Arch. Pharm. Res.37 ( 3 ), 299 – 305 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gebert LF , RebhanMA , CrivelliSE , DenzlerR , StoffelM , HallJ . Miravirsen (SPC3649) can inhibit the biogenesis of miR-122 . Nucleic Acids Res.42 ( 1 ), 609 – 621 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lanford RE , Hildebrandt-EriksenES , PetriAet al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection . Science327 ( 5962 ), 198 – 201 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hildebrandt-Eriksen ES , AarupV , PerssonR , HansenHF , MunkME , OrumH . A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys . Nucleic Acid Ther.22 ( 3 ), 152 – 161 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Janssen HL , ReesinkHW , LawitzEJet al. Treatment of HCV infection by targeting microRNA . N. Engl. J. Med.368 ( 18 ), 1685 – 1694 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Watashi K , HijikataM , HosakaM , YamajiM , ShimotohnoK . Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes . Hepatology38 ( 5 ), 1282 – 1288 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Inoue K , SekiyamaK , YamadaM , WatanabeT , YasudaH , YoshibaM . Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial . J. Gastroenterol.38 ( 6 ), 567 – 572 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Hopkins S , ScorneauxB , HuangZet al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro . Antimicrob. Agents Chemother.54 ( 2 ), 660 – 672 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Paeshuyse J , KaulA , De ClercqEet al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro . Hepatology43 ( 4 ), 761 – 770 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Flisiak R , FeinmanSV , JablkowskiMet al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients . Hepatology49 ( 5 ), 1460 – 1468 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Flisiak R , HorbanA , GallayPet al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus . Hepatology47 ( 3 ), 817 – 826 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Flisiak R , JaroszewiczJ , FlisiakI , LapinskiT . Update on alisporivir in treatment of viral hepatitis C . Expert Opin. Investig. Drugs21 ( 3 ), 375 – 382 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gallay PA , LinK . Profile of alisporivir and its potential in the treatment of hepatitis C . Drug Des. Devel. Ther.7 , 105 – 115 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Nilsson J , MossS , CoatesN , BobardtM , GallayP , GregoryM . NVP018, a cyclophilin inhibitor for treatment of chronic HBV infection . J. Hepatol.60 ( 1 ), S423 ( 2014 ).
   Google Scholar
• Tanaka Y , SatoY , SasakiT . Suppression of coronavirus replication by cyclophilin inhibitors . Viruses5 ( 5 ), 1250 – 1260 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hanoulle X , BadilloA , WieruszeskiJMet al. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B . J. Biol. Chem.284 ( 20 ), 13589 – 13601 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Verdegem D , BadilloA , WieruszeskiJMet al. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A . J. Biol. Chem.286 ( 23 ), 20441 – 20454 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Coelmont L , HanoulleX , ChatterjiUet al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A . PLoS ONE5 ( 10 ), e13687 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kaul A , StaufferS , BergerCet al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics . PLoS Pathog.5 ( 8 ), e1000546 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Liu Z , YangF , RobothamJM , TangH . Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex . J. Virol.83 ( 13 ), 6554 – 6565 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Madan V , PaulD , LohmannV , BartenschlagerR . Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation . Gastroenterology146 ( 5 ), 1361 – 1372 . e1361 – e1369 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bedard KM , WangML , ProllSCet al. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses . J. Virol.86 ( 13 ), 7334 – 7344 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bergmann JF , de BruijneJ , HothoDMet al. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV . Aliment. Pharmacol. Ther.34 ( 4 ), 443 – 453 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Boonstra A , LiuBS , GroothuisminkZMet al. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7 . Antivir. Ther.17 ( 4 ), 657 – 667 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fidock MD , SouberbielleBE , LaxtonCet al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691) . Clin. Pharmacol. Ther.89 ( 6 ), 821 – 829 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Horsmans Y , BergT , DesagerJPet al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection . Hepatology42 ( 3 ), 724 – 731 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Wang N , LiangY , DevarajS , WangJ , LemonSM , LiK . Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells . J. Virol.83 ( 19 ), 9824 – 9834 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• O’Brien TR . Interferon-alfa, interferon-lambda and hepatitis C . Nat. Genet.41 ( 10 ), 1048 – 1050 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zeuzem S , AroraA , BaconBet al. PegInterferon Lambda 1A (Lambda) compared with pegInterferon alfa-2A (ALFA) in treatment-naive patients with HCV genotypes (G) 2 or 3: first SVR24 results from EMERGE Phase IIB . J. Hepatol.56 , S1 – S20 ( 2012 ).
   PubMedGoogle Scholar
• Everson GT , SimsKD , Rodriguez-TorresMet al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection . Gastroenterology146 ( 2 ), 420 – 429 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kowdley K , LawitzE , PoordadFet al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/-ribavirin in patients with chronic HCV GT-1 infection: results from the aviator study . J. Hepatol.58 , S2 ( 2013 ).
   Google Scholar
• Afdhal N , ZeuzemS , KwoPet al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection . N. Engl. J. Med.370 ( 20 ), 1889 – 1898 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Feld JJ , KowdleyKV , CoakleyEet al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin . N. Engl. J. Med.370 ( 17 ), 1594 – 1603 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zeuzem S , JacobsonIM , BaykalTet al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin . N. Engl. J. Med.370 ( 17 ), 1604 – 1614 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM . New hepatitis C therapies: the toolbox, strategies, and challenges . Gastroenterology146 ( 5 ), 1176 – 1192 ( 2014 ).
   PubMed Web of Science ®Google Scholar